Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00443534 · ClinicalTrials.gov registry record · NA
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
A NA study of Neoplasms, sponsored by Pfizer.
- Completed
- Registry status
- NA
- Development phase
- 123
- Enrollment target
- 20
- Study locations
NCT00443534: Completed NA study of Neoplasms, sponsored by Pfizer.
NCT00443534 is a NA study of Neoplasms that has completed, run by Pfizer. The registered enrollment target is 123 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00443534, a NA study of Neoplasms, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- NA
- Development phase
- 123 participants
- Enrollment target
- 20
- Study locations
Study Summary
This protocol allows subjects who have participated in a previous SU011248 protocol the ability to continue to receive SU011248 after their study has ended.
Primary Outcome
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Conditions Studied
Interventions
- DRUG SU011248
Study Locations (20)
Illinois
- Pfizer Investigational Site - Harvey
- Pfizer Investigational Site - Harvey
- Pfizer Investigational Site - Maywood
- Pfizer Investigational Site - Tinley Park
- Pfizer Investigational Site - Zion
Missouri
- Pfizer Investigational Site - City of Saint Peters
- Pfizer Investigational Site - Creve Coeur
- Pfizer Investigational Site - St Louis
North Carolina
- Pfizer Investigational Site - Chapel Hill
- Pfizer Investigational Site - Clinton
- Pfizer Investigational Site - Goldsboro
Colorado
- Pfizer Investigational Site - Aurora
- Pfizer Investigational Site - Littleton
Florida
- Pfizer Investigational Site - Orlando
Georgia
- Pfizer Investigational Site - Atlanta
Indiana
- Pfizer Investigational Site - Munster
Maryland
- Pfizer Investigational Site - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2006-05 |
| Est. Completion | 2011-12 |
| Phase | NA |
What the finished NCT00443534 record still lists
NCT00443534 is an interventional study that assigns participants to a tested intervention. The registered 123 participants enrollment target is mid-sized for trials with a published cap, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which SU011248 is the first listed.
NCT00443534 names 20 study sites across 11 states, led by Illinois, Missouri, North Carolina.
Frequently Asked Questions
What is clinical trial NCT00443534 about?
NCT00443534 is a clinical study titled "A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.". This protocol allows subjects who have participated in a previous SU011248 protocol the ability to continue to receive SU011248 after their study has ended.
What is the current status of trial NCT00443534?
This trial is currently completed. It is a NA study. The enrollment target is 123 participants. The study started on 2006-05. Estimated completion is 2011-12.
What conditions does trial NCT00443534 study?
This clinical trial studies the following conditions: Neoplasms.
What interventions are being tested in trial NCT00443534?
The interventions under investigation include: SU011248 (DRUG).
Who is sponsoring clinical trial NCT00443534?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00443534 being conducted?
This trial has 20 study locations across Colorado, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00443534's enrollment target sits among peer trials
123 63rd of 158 higher than 96 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Endometrial Cell Collection With the PadKit
RECRUITING · NA
-
Serious Gaming for Chemotherapy-induced Nausea and Vomiting
RECRUITING · NA
-
Biennial CEM in Women With a Personal History of Breast Cancer
RECRUITING · NA
-
LITT Followed by Hypofractionated RT for Recurrent Gliomas
RECRUITING · NA
-
Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy
RECRUITING · NA
-
Screening Strategies Among High-risk Populations for Anal Cancer
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05285891 · 123 participants · Phase 4
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
- NCT05334368 · 123 participants · Phase 3
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
- NCT06088355 · 123 participants · NA
Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease
- NCT06111131 · 123 participants · NA
Ancora-SB Overtube Complete Positioning and Optical Visualization During Endoscopic Procedures
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia